Goldman Sachs Group Inc. Acquires 12,647 Shares of Lifecore Biomedical, Inc. $LFCR

Goldman Sachs Group Inc. lifted its position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 16.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 87,998 shares of the company’s stock after acquiring an additional 12,647 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.24% of Lifecore Biomedical worth $620,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in LFCR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Lifecore Biomedical by 14.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock valued at $104,000 after purchasing an additional 1,886 shares during the last quarter. Summit Securities Group LLC bought a new stake in Lifecore Biomedical in the first quarter valued at about $26,000. Boston Partners bought a new stake in Lifecore Biomedical in the first quarter valued at about $241,000. Nuveen LLC bought a new stake in Lifecore Biomedical in the first quarter valued at about $203,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Lifecore Biomedical by 6.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 79,495 shares of the company’s stock valued at $560,000 after purchasing an additional 5,068 shares during the last quarter. Institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Stock Down 10.8%

Shares of Lifecore Biomedical stock opened at $7.05 on Thursday. Lifecore Biomedical, Inc. has a 1 year low of $4.33 and a 1 year high of $8.85. The business has a 50-day moving average of $7.49 and a two-hundred day moving average of $7.07. The company has a market capitalization of $263.95 million, a P/E ratio of -5.38 and a beta of 0.64. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.84 and a quick ratio of 1.77.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Lifecore Biomedical had a negative return on equity of 846.51% and a negative net margin of 31.70%.The business had revenue of $36.44 million during the quarter, compared to the consensus estimate of $35.36 million. Lifecore Biomedical has set its FY 2026 guidance at EPS. As a group, equities analysts predict that Lifecore Biomedical, Inc. will post -0.91 EPS for the current year.

Analysts Set New Price Targets

LFCR has been the subject of a number of recent analyst reports. Wall Street Zen upgraded Lifecore Biomedical from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. KeyCorp initiated coverage on Lifecore Biomedical in a report on Wednesday, September 3rd. They issued a “sector weight” rating for the company. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.